Clinical Trial Update: Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways [Phase 3]

View source ↗

Summary

Phase 3 safety results for AZLI in children with cystic fibrosis and chronic Pseudomonas aeruginosa infection have been posted. The trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Infection

Drugs mentioned

• AZLI (Aztreonam for inhalation)

Snippet

Sponsor: Gilead Sciences | Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 3 | Status: COMPLETED | Results posted: 2014-05-01